1. Clinical Response Is Associated with Elevated Plasma Interleukin-1 Receptor Antagonist During Selective Granulocyte and Monocyte Apheresis in Patients with Ulcerative Colitis
- Author
-
Yuji Takeda, Katsuya Hiraishi, Kyoya Sakimura, Takeshi Yoshida, Yoshikazu Tsuzuki, Fumio Konishi, Abbi R. Saniabadi, Soichiro Miura, Kenji Fujimori, Tatsuo Ide, Souichi Sugawara, Shinichi Ota, Hiromichi Suzuki, Hiroo Anzai, Etsuro Iwashita, Toshihide Omori, and Yukio Yoshida
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Physiology ,medicine.drug_class ,Sialoglycoproteins ,Enzyme-Linked Immunosorbent Assay ,Severity of Illness Index ,Gastroenterology ,Inflammatory bowel disease ,Monocytes ,Internal medicine ,Blood plasma ,medicine ,Humans ,Leukapheresis ,Colitis ,Aged ,business.industry ,Remission Induction ,Receptors, Interleukin-1 ,Interleukin ,Middle Aged ,medicine.disease ,Receptor antagonist ,Ulcerative colitis ,Blood Cell Count ,Interleukin 1 Receptor Antagonist Protein ,Treatment Outcome ,Interleukin 1 receptor antagonist ,Rheumatoid arthritis ,Immunology ,Colitis, Ulcerative ,Female ,business ,Granulocytes - Abstract
Depletion of granulocytes and monocytes (GM) by selective apheresis (GMA) with an Adacolumn exerts an anti-inflammatory effect in patients with ulcerative colitis (UC) or rheumatoid arthritis. However, the mechanism of the anti-inflammatory effect of GMA is not fully understood yet. We investigated the effect of GMA on the plasma concentration of interleukin-1 receptor antagonist (IL-1ra), a potent anti-inflammatory cytokine. Twenty-six patients with active UC received GMA at one session per week for 5 consecutive weeks. Clinical response was defined as Deltaclinical activity index (DeltaCAI=CAI at entry - CAI at post)or=4, while clinical remission was defined as CAIor=4. Twenty-one of twenty-six patients (80.8%) responded to GMA. In the first session, plasma from responder patients showed a significant (P0.01) increase in IL-1ra in the Adacolumn outflow. In contrast, there was no change in IL-1ra in nonresponders. In conclusion, release of IL-1ra during GMA might be one mechanism of clinical efficacy associated with this therapy.
- Published
- 2006